Energy performance certificate classifications across shifting frameworks

AbstractLarge amounts of valuable data are being collected in the energy performance certificate (EPC) schemes. These data offer a huge potential, in terms of enabling researches to study energy demand in buildings and related causalities. However, revisions of the national schemes and calculation methods necessitate a standardization of the results from the various schemes.The primary focus of this research is on checking the consistency of converting labels with a given classification from an old scheme directly into that of a newer scheme. Furthermore, a general check is carried out, to review the consistency within each scheme, since the collected data are handled by several stakeholders which use different calculation tools.In the study, several instances were found, where a simple conversion of a building's energy label classification did not agree with the classification calculated anew, according to the present scheme. The number of inconsistent records was found to vary from scheme to scheme; most of the inconsistent classifications were found in the early schemes however. Fortunately, most information is stored at a disaggregated level, which means that classifications can easily be recalculated. In addition to the inconsistent EPC classifications, a number of corrupt records were observed, in which the energy frame did not seem to agree with the calculated energy demand for heating and electricity

Functional Compost

The aim of the research program Functional Compost is to develop and test compost, which have been enriched with chitin, for plant growth promoting properties and to recognise specific mechanisms. Two types of compost were included in the program: source separated biodegradable municipal solid waste compost (DM = 62 %) and garden and park waste compost (DM = 66 %). Chitin was added in trace amounts during the maturity phase, combined with two levels of trace amounts immediately before adding the compost to the growth medium. The research program includes several parallel experiments. In experiment I, compost (20 vol. %) was added to soil (no plants) and incubated at 15 C for 5 month, under regular determination of microbial respiration and gross and net N mineralization. There was a significant increase in respiration due to chitin enrichment, which could not be explained by the amount of C derived from the chitin, which therefore suggest a priming effect. The N analyses are still being processed in the laboratory, but data are expected to be available at the conference. In experiment II, compost was mixed with sand, put into pots in a climate chamber, and spring barley seeds infected with Fusarium culmorum were sown in the pots. After 3 weeks of growth, the health of the plants was determined, and the chitinase activity in the sand was measured. The health of the plants and the chitinase activity was significantly higher in the treatments receiving municipal waste compared to the treatments receiving garden waste compost. However, there was no clear effect of the chitin enrichment. Additionally, the microbial community structure of the two types of compost, with and without early chitin, was determined by Denaturing Gradient Gel Electrophoresis (DGGE). There was a clear separation between compost types, and with or without early chitin amendment. Experiment III is a regular growth experiment, and is running right now. Compost has been incorporated into soil, put into pots in the greenhouse, and spring barley is grown for 2 month before determination for wet and dry weight and N uptake. Data from experiment III is expected to be available at the conference

Investigation of the potential association between the use of fluoxetine and occurrence of acute pancreatitis: a Danish register-based cohort study

BACKGROUND: There is currently conflicting evidence of the association between the use of selective serotonin reuptake inhibitors (SSRIs) and acute pancreatitis. The SSRI fluoxetine has been suspected to be the driver of this serious outcome. Therefore, this study aims to investigate the potential association between fluoxetine use and the occurrence of acute pancreatitis. METHODS: We conducted a nationwide cohort study using Danish register-based data from 1996 to 2016. The exposed group were new users of fluoxetine (1-year washout). The control subjects were new users of citalopram or SSRIs, excluding fluoxetine. The outcome was an incident diagnosis of acute pancreatitis with a 5-year washout. We used an intention-to-treat approach following patients for a maximum of 6 months. Cox regression analyses were performed, estimating hazard ratios (HRs) and 95% confidence intervals (CIs) adjusted for age/sex, comorbidities and co-medications, using propensity score adjustment and matching. RESULTS: In the propensity score-matched analyses, 61 783 fluoxetine users were included. The incidence rates among users of fluoxetine and other SSRIs were 5.33 (3.05-8.66) and 5.36 (3.06-8.70) per 10 000 person-years, respectively. No increased risk of acute pancreatitis was identified following fluoxetine exposure compared with either citalopram [HR 1.00, 95% CI 0.50-2.00) or other SSRIs (0.76, 0.40-1.46). CONCLUSIONS: Fluoxetine use was not associated with an increased risk of acute pancreatitis compared with citalopram or other SSRIs. The absolute risk of acute pancreatitis was low and did not vary between different SSRIs. Further research is needed to determine whether there is a class effect on the risk of acute pancreatitis

Impact of 2018 EU Risk Minimisation Measures and Revised Pregnancy Prevention Programme on Utilisation and Prescribing Trends of Medicinal Products Containing Valproate: An Interrupted Time Series Study

Introduction: Due to established teratogenicity of valproates, the EU risk minimisation measures (RMMs) with a pregnancy prevention programme (PPP) for valproate were updated in March 2018. Objectives: To investigate the effectiveness of the 2018 EU RMMs on valproate utilisation in five European countries/regions. Methods: A multi-database, times series study of females of childbearing potential (12–55 years) was conducted using electronic medical records from five countries/regions (01.01.2010–31.12.2020): Denmark, Tuscany (Italy), Spain, the Netherlands, and the UK. Clinical and demographic information from each database was transformed to the ConcePTION Common Data Model, quality checks were conducted and a distributed analysis was performed using common scripts. Incident and prevalent use of valproate, proportion of discontinuers and switchers to alternative medicine, frequency of contraception coverage during valproate use, and occurrence of pregnancies during valproate exposure were estimated per month. Interrupted time series analyses were conducted to estimate the level or trend change in the outcome measures. Results: We included 69,533 valproate users from 9,699,371 females of childbearing potential from the five participating centres. A significant decline in prevalent use of valproates was observed in Tuscany, Italy (mean difference post-intervention −7.7%), Spain (−11.3%), and UK (−5.9%) and a non-significant decline in the Netherlands (−3.3%), but no decline in incident use after the 2018 RMMs compared to the period before. The monthly proportion of compliant valproate prescriptions/dispensings with a contraceptive coverage was low (<25%), with an increase after the 2018 RMMs only in the Netherlands (mean difference post-intervention 12%). There was no significant increase in switching rates from valproates to alternative medicine after the 2018 intervention in any of the countries/regions. We observed a substantial number of concurrent pregnancies during valproate exposure, but with a declining rate after the 2018 RMMs in Tuscany, Italy (0.70 per 1000 valproate users pre- and 0.27 post-intervention), Spain (0.48 and 0.13), the Netherlands (0.34 and 0.00), and an increasing rate in UK (1.13 and 5.07). Conclusion: There was a small impact of the 2018 RMMs on valproate use in the studied European countries/regions. The substantial number of concurrent pregnancies with valproate exposure warrants a careful monitoring of implementation of the existing PPP for valproate in clinical practice in Europe, to see if there is any need for additional measures in the future